Market Cap | 26.50M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -16.22M | Forward P/E | -1.04 | EPS next Y | - | 50D Avg Chg | -93.00% |
Sales | 49k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -94.00% |
Dividend | N/A | Price/Book | 1.21 | EPS next 5Y | - | 52W High Chg | -97.00% |
Recommedations | 3.00 | Quick Ratio | 1.50 | Shares Outstanding | 62.36M | 52W Low Chg | 1.00% |
Insider Own | 29.92% | ROA | -15.19% | Shares Float | 43.91M | Beta | 1.35 |
Inst Own | 5.57% | ROE | -32.32% | Shares Shorted/Prior | 427.28K/520.17K | Price | 0.43 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 34,017 | Target Price | - |
Oper. Margin | -35,422.45% | Earnings Date | Mar 29 | Volume | 371,878 | Change | -23.04% |
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Wedbush | Neutral | Mar 19, 21 |
Barclays | Equal-Weight | Mar 19, 21 |
JMP Securities | Market Perform | Mar 19, 21 |
HC Wainwright & Co. | Neutral | Mar 19, 21 |
JP Morgan | Neutral | Mar 19, 21 |
Barclays | Overweight | Nov 25, 20 |
Wedbush | Outperform | Nov 25, 20 |
Baird | Outperform | Nov 25, 20 |
JMP Securities | Market Outperform | Nov 25, 20 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
MILANO VINCENT | President & CEO President & CEO | Dec 22 | Sell | 4.32 | 37,169 | 160,570 | 214,561 | 12/22/20 |